Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 56
- Registration Number
- NCT02300545
- Locations
- 🇺🇸
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Mayo Clinic - Phoenix, Phoenix, Arizona, United States
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 300
- Registration Number
- NCT02282579
- Locations
- 🇪🇸
Hospital Provincial de Pontevedra, Pontevedra, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)
- Conditions
- Penile Squamous Cell Carcinoma Stage IV
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 4
- Registration Number
- NCT02279576
- Locations
- 🇪🇸
Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain
🇪🇸Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Universitario Lucus Augusti, Lugo, Spain
Evaluation of Votrient in Angiosarcoma
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 26
- Registration Number
- NCT02212015
- Locations
- 🇦🇹
Universitätsklinik Wien, Wien, Austria
🇩🇪Helios-Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Helios Klinikum Berlin-Buch, Berlin, Germany
Pazopanib Maintenance Phase II
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 1
- Registration Number
- NCT02207309
- Locations
- 🇩🇪
Ludwig-Maximilians University of Munich, Klinikum Großhadern, Munich, Bavaria, Germany
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
- Conditions
- Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02204371
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Pazopanib Vs. Pazopanib Plus Gemcitabine
- Conditions
- Leiomyosarcoma or Carcinosarcoma
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 58
- Registration Number
- NCT02203760
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Helios Klinikum Berlin-Buch, Klinik für Onkologie und Paliativmedizin, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum, Bad Saarow, Germany
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
- Conditions
- Carcinoma, Non-Small Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT02193152
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Conditions
- Angiomatoid Fibrous HistiocytomaEpithelioid SarcomaIntimal SarcomaMalignant Skin Granular Cell TumorMalignant Triton TumorUndifferentiated High Grade Pleomorphic Sarcoma of BoneAtypical FibroxanthomaClear Cell Sarcoma of Soft TissueLow Grade Myofibroblastic SarcomaMyxofibrosarcoma
- Interventions
- Radiation: Radiation TherapyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 140
- Registration Number
- NCT02180867
- Locations
- 🇺🇸
The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Pazopanib Tolerability When Given With Food
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 78
- Registration Number
- NCT02138526
- Locations
- 🇳🇱
RadboudUMC, Nijmegen, Gelderland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.